MOSCOW (Reuters) – Russian pharmaceutical company Petrovax on Thursday said 92.5% of Russian volunteers in trials of the Chinese Ad5-Ncov vaccine against COVID-19 had shown high levels of antibodies, the Interfax news agency reported.
Ad5-nCoV is a candidate vaccine co-developed by CanSino Biologics and a Chinese military-backed research unit.
(Reporting by Alexander Marrow; editing by John Stonestreet)
The first round of the NFL draft turns into a QB bonanza with a record-setting 6 taken in the top 12
Joel Embiid scores 50 points to lead 76ers past Knicks 125-114 to cut deficit to 2-1
Sergei Bobrovsky makes 26 saves, Panthers beat Lightning 5-3 to take 3-0 series lead
Falcons provide an NFL draft surprise by taking Washington QB Michael Penix Jr. with No. 8 pick
Rory McIlroy and Shane Lowry share lead in team event at TPC of Louisiana
US-China talks start with warnings about misunderstandings and miscalculations
Paramedic sentencing in Elijah McClain’s death caps trials that led to 3 convictions
‘There’s Still Tomorrow’ director Paola Cortellesi talks success, toxic relationships and hope
South Africa to mark 30 years of freedom amid inequality, poverty and a tense election ahead
‘The movement will persist’: Advocates stress Weinstein reversal doesn’t derail #MeToo reckoning
17 states challenge federal rules entitling workers to accommodations for abortion
New York City to require warning labels for sugary foods and drinks in chain restaurants
Selling weight-loss and muscle-building supplements to minors in New York is now illegal
Minneapolis smokers to pay some of the highest cigarette prices in US with a $15 per-pack minimum
